Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Circassia's Harris Deeply Frustrated By Phase III Cat Allergy Flop

Executive Summary

The UK biotech’s potential revolutionary approach to allergies has failed to achieve its primary endpoint in a Phase III study, halting much of its research in the allergy area and casting a shadow over UK innovation.

You may also be interested in...

Phase III Beckons For A Short-Course Seasonal Allergic Rhinitis Jab

A marketing approval for a seasonal allergic rhinitis vaccine from Allergy Therapeutics has moved nearer with positive top-line Phase II results that define the dose to be used in a Phase III study.

Circassia Builds US Respiratory Presence with AstraZeneca Deal

Circassia has put memories of last year's Cat-SPIRE disappointment firmly behind it with a new deal with AstraZeneca for Tudorza and Duaklir in COPD that will allow it to concentrate on boosting its respiratory franchise.

UK Health-Care Investors ‘Not As Brave Or Audacious’ As Those In US

At a recent UK health-care conference, experts from across the health-care sector and investment community came together to explore alternative financing tactics to support businesses in their growth plans. UK investors were warned that if they continue to be overly cautious, they might risk losing out to their transatlantic counterparts.

Related Content


Related Companies

Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts